OncoMatch/Clinical Trials/NCT07803081
Radiotherapy and Long-term Outcomes in Early Breast Cancer With SLNB Omission
Is NCT07803081 recruiting? Yes, currently enrolling (Sep 2026).
This prospective, multicenter observational cohort study evaluates long-term outcomes in patients with early-stage invasive breast cancer who undergo breast-conserving surgery without sentinel lymph node biopsy or other axillary surgery and subsequently receive adjuvant radiotherapy. The study will evaluate recurrence, survival, radiotherapy-related toxicities, and quality of life. Radiotherapy will be delivered according to routine clinical practice at each participating institution without protocol-mandated treatment assignment. Detailed radiotherapy characteristics, including treatment volume, technique, dose and fractionation, tumor-bed boost, and radiation dose to axillary lymph node levels I-III, will be prospectively collected to evaluate their associations with clinical outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Demographics
Prior therapy
Cannot have received: neoadjuvant systemic therapy
Receipt of neoadjuvant systemic therapy before breast cancer surgery
Cannot have received: radiotherapy to the ipsilateral breast or chest region
Prior radiotherapy to the ipsilateral breast or chest region
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07803081 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant systemic therapy, radiotherapy to the ipsilateral breast or chest region disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages